An Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients

A Multi-center, Prospective, Observational Study to Evaluate the Safety and Efficacy of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients

This study aims to evaluate the status of AE and improvement effect of K-CAB Tab/K-CAB ODT(Tegoprazan) 50mg in patients with GERD.

This is a multi-center, prospective, non-interventional, observational study. Subjects will be prescribed in one of the two formulation groups (K-CAB Tab 50 mg or K-CAB ODT 50 mg).

Inclusion Criteria:

1. Subjects over 19 years of age as of the date of consent
2. Subjects with a total score of 8 or more in the Korean Gastroesophageal Reflux Disease Questionnaire (GerdQ) based on Visit 1
3. Subjects who voluntarily decides to participate and agrees in writing to the consent form of the study

Exclusion Criteria:

1. Subjects who have hypersensitivity reactions and a medical history of Benzimidazole or components of the investigational drug
2. Subjects on Atazanavir, Nelfinavir, or Rilpivirine-containing medications
3. Pregnant and lactating women